Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a…
George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Associations Scientific Sessions 2025
London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage…
Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a…
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Valneva Announces Lifting of European Medicines Agencys Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ in Elderly
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext…
